{"id":"pb-6-doses-rifampicin-and-dapsone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemolytic anemia"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Methemoglobinemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampicin inhibits bacterial RNA polymerase, disrupting transcription in Mycobacterium leprae, while dapsone inhibits dihydropteroate synthase in the folate synthesis pathway. Together, these agents provide synergistic bactericidal and bacteriostatic activity against the causative agent of leprosy, reducing bacterial load and preventing resistance.","oneSentence":"PB 6 doses is a fixed-dose combination of rifampicin and dapsone that inhibits bacterial cell wall and folate synthesis to treat leprosy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:05.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Leprosy (paucibacillary and multibacillary forms)"}]},"trialDetails":[{"nctId":"NCT00669643","phase":"PHASE4","title":"Uniform Multidrug Therapy Regimen for Leprosy Patients","status":"COMPLETED","sponsor":"University of Brasilia","startDate":"2007-02","conditions":"Leprosy","enrollment":859},{"nctId":"NCT01885611","phase":"PHASE1, PHASE2","title":"Virgin Coconut Oil Oral Supplementation for Leprosy Patients","status":"WITHDRAWN","sponsor":"Philippine Dermatological Society","startDate":"2013-06","conditions":"Hansen's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PB 6 doses of 2 drugs"],"phase":"marketed","status":"active","brandName":"PB 6 doses - Rifampicin and Dapsone","genericName":"PB 6 doses - Rifampicin and Dapsone","companyName":"University of Brasilia","companyId":"university-of-brasilia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PB 6 doses is a fixed-dose combination of rifampicin and dapsone that inhibits bacterial cell wall and folate synthesis to treat leprosy. Used for Leprosy (paucibacillary and multibacillary forms).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}